Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2016-11-08 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
第六届董事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from 普洛药业股份有限公司, detailing the approval of a land transfer proposal during the 28th meeting of the 6th board. It includes meeting attendance, voting results, and compliance with company law and articles of association. There is no financial data, audit information, or report publication mentioned. The content fits the category of Board/Management Information (MANG) as it relates to board decisions and resolutions.
2016-11-08 Chinese
2016年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 Third Quarter Report" of 普洛药业股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data such as total assets, net profit, earnings per share, and shareholder information for the third quarter of 2016. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length (7782 characters) and content confirm it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2016
2016-10-27 Chinese
2016年第三季度报告全文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2016 Third Quarter Report" of 普洛药业股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including consolidated balance sheets, profit and loss statements, and notes on financial data for the third quarter of 2016. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it includes actual financial statements rather than just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2016
2016-10-27 Chinese
关于公司高管辞职的公告
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the resignation of a company's senior executive (vice general manager). It includes no financial data, no report content, and is focused solely on management change. The document length is only 411 characters, indicating it is a brief notice. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2016-10-09 Chinese
关于收到《药物临床试验批件》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving a clinical trial approval from the national drug regulatory authority. It details the drug name, clinical trial phase, regulatory approval, and potential impact on the company. The document is short (1345 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. The content is a regulatory announcement about drug trial approval, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2016-09-09 Chinese
关于公司管理层成立合伙企业继续增持公司股份的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the company's management team forming a partnership enterprise to continue increasing their shareholding in the company. It details the number of shares purchased, the method of purchase, and future plans for further share acquisition. This fits the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels. The document is not a financial report, earnings release, or regulatory filing but specifically concerns shareholding changes by insiders or related parties.
2016-08-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.